Related Business Topics
Latest Headlines
Forbes.com - Nov. 23, 2009, 6:15 PM
revenues. Economic data weigh on Europe as oil prices move past $7 a barrel. Dow Nears 0,000 After hours: Investors gear up for Onyx Pharmaceuticals buys cancer drug developer. Google earnings SEC investigates KB . Asia Update Japanese prime minister ...
Forbes.com - Nov. 20, 2009, 3:32 PM
Retailer says dip may continue. Europe and Asia struggle for gains as Spain remains stuck in recession. HP Buys Com After hours: COM shares Applied Materials and Green Mountain Coffee beat. Chief executive may be ready to Macy's sales tumble. Chinese ...
Forbes.com - Nov. 18, 2009, 11:00 AM
Cadbury. After hours: Late traders bet Kraft will sweeten deal for British candy maker. Retail jobless claims. 0.% Fannie requests $ billion Asia Update Dalai Lama plans controversial Profits up for Japanese automakers. U.S. Jobless Hits 0.% Global ...
Forbes.com - Nov. 9, 2009, 4:54 PM
SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2009. Arena reported a lower net loss allocable to common stockholders in the third ...
CNBC - Nov. 9, 2009, 4:34 PM
USA Today - Oct. 27, 2009, 10:53 AM
At least three new prescription diet drugs are in the final stages of development as pharmaceutical companies race to see which one will have the next big diet medication to hit the market. OBESITY: Costs double to $147B a year PERSONAL LEVEL: Doctors ...
Forbes.com - Oct. 26, 2009, 3:49 PM
BusinessWire - PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring ...
CNBC - Oct. 26, 2009, 1:27 PM
NEW YORK - Shares of three obesity drug developers moved higher Monday as the companies presented further information about their drug candidates at a medical conference. Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus Inc. have all ...
BusinessWeek - Oct. 26, 2009, 12:47 PM
Shares of three obesity drug developers moved higher Monday as the companies presented further information about their drug candidates at a medical conference. Arena Pharmaceuticals Inc Vivus said patients who took its drug candidate, Qnexa, lost about ...
CNBC - Oct. 26, 2009, 11:46 AM
Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months. Now, CEO Leland Wilson is carrying that load up to Capitol Hill. While he's in town for the annual Obesity Society meeting, Wilson is trying to make ...
